| 0 (0%) | 12-27 04:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 63.24 | 1-year : | 63.58 |
| Resists | First : | 54.15 | Second : | 54.43 |
| Pivot price | 53.92 |
|||
| Supports | First : | 53.68 | Second : | 44.66 |
| MAs | MA(5) : | 53.87 |
MA(20) : | 53.97 |
| MA(100) : | 53.95  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 50.8 |
D(3) : | 31.5 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 54.56 | Low : | 50.52 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IGIB ] has closed below upper band by 26.7%. Bollinger Bands are 45.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 54.11 - 54.33 | 54.33 - 54.55 |
| Low: | 53.4 - 53.63 | 53.63 - 53.86 |
| Close: | 53.65 - 54.04 | 54.04 - 54.45 |
Wed, 24 Dec 2025
Noteworthy ETF Outflows: IGIB - Nasdaq
Wed, 24 Dec 2025
BD Biosciences, CSIR-IGIB launch Centre of Excellence for single-cell multiomics - ET HealthWorld
Tue, 23 Dec 2025
BD Biosciences and CSIR- IGIB inaugurate its first centre of excellence for single-cell multiomics - Pharmabiz.com
Sat, 20 Dec 2025
Trading Systems Reacting to (IGIB) Volatility - Stock Traders Daily
Wed, 10 Dec 2025
How Ishares Intermediate Credit Bond Etf (IGIB) Affects Rotational Strategy Timing - Stock Traders Daily
Thu, 20 Nov 2025
India Launches Clinical Trials for Sickle Cell Disease Treatment - India News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|